Shares of Gland Pharma dropped 6% to Rs 1,745 on BSE as entities related to ex-promoter Dr Ravi Penmetsa sold 5.5% equity. Large block deal...

Nicomac Machinery and RP Advisory Services are looking at raising Rs 1,400 crore through the sale, and have set the floor price for the sam...

KP Advisory Services, the family office of the promoter Ravi Penmetsa, acquired the five-star property last week in Coimbatore under the co...

Data from the recent deal flows also suggest that many of these financial investors are also willing to pay more than strategics. Historica...

Gland Pharma, which is owned 74% by the Chinese major, is seeking a valuation of $3 billion, which is more than twice that of the valuation...

Fosun Pharma and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added.

Last year, the government relaxed the foreign investment rules, allowing global companies to acquire up to 74 per cent in local drug makers...

The deal with Fosun is also an example of the excellence of India’s manufacturing capabilities. It goes with the essence of the Make in Ind...

The deal would be the first major move by the Fosun group since Guo Guangchang, founder of flagship holding firm Fosun International Ltd an...

Shanghai Fosun will acquire the shares held by Gland Pharma founders Ravi Penmetsa and his family and PE giant KKR.

Fosun has agreed to acquire 96 percent stake, which includes shares held by founders of Gland Pharma Ravi Penmetsa and family and private e...

Coming from behind in a closely fought race that saw US giant Baxter and private equity fund Advent make firm offers early May, Hong Kong-l...

Hyderabad-headquartered Gland is a leading contract manufacturers of injectables, supplying to pharma majors in India and US like Dr Reddy’...

If the deal materialises, the promoter family of Ravi Penmetsa may sell its entire equity stake of nearly 60% for a valuation of over $1.2 ...

Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block.

The two-part transaction, likely to be announced this week, is a combination of fresh equity infusion and a buyout of Evolvance India Life ...

Gland Pharma promoters and vice chairman Ravi Penmetsa and Sanjay Nayar, MD and chief executive officer of KKR declined comments.